Malignant Ovarian Tumor in Children

소아에 발생한 악성 난소 종양

  • Shin, Hye-Ah (Division of Pediatric surgery, Asan Medical Center Children Hospital, Ulsan University School of Medicine) ;
  • Kim, Dae-Yeon (Division of Pediatric surgery, Asan Medical Center Children Hospital, Ulsan University School of Medicine) ;
  • Cho, Min-Jeong (Division of Pediatric surgery, Asan Medical Center Children Hospital, Ulsan University School of Medicine) ;
  • Kim, Tae-Hoon (Division of Pediatric surgery, Asan Medical Center Children Hospital, Ulsan University School of Medicine) ;
  • Kim, Seong-Chul (Division of Pediatric surgery, Asan Medical Center Children Hospital, Ulsan University School of Medicine) ;
  • Kim, In-Koo (Division of Pediatric surgery, Asan Medical Center Children Hospital, Ulsan University School of Medicine)
  • 신혜아 (울산대학교 의과대학 서울아산병원 소아청소년병원 소아외과) ;
  • 김대연 (울산대학교 의과대학 서울아산병원 소아청소년병원 소아외과) ;
  • 조민정 (울산대학교 의과대학 서울아산병원 소아청소년병원 소아외과) ;
  • 김태훈 (울산대학교 의과대학 서울아산병원 소아청소년병원 소아외과) ;
  • 김성철 (울산대학교 의과대학 서울아산병원 소아청소년병원 소아외과) ;
  • 김인구 (울산대학교 의과대학 서울아산병원 소아청소년병원 소아외과)
  • Received : 2010.06.03
  • Accepted : 2010.09.08
  • Published : 2010.12.31

Abstract

Malignant ovarian tumors in children are very rare, and consist of about 1 % of all childhood malignant tumors. The purpose of this study is to examine the clinical characteristics, treatment, and prognosis for children with malignant ovarian tumors. We retrospectively reviewed the medical records of children under 15 years of age with malignant ovarian tumors who had been treated surgically at Asan Medical Center between 1989 and March 2009. There were 32 patients, ranged in age at surgery from 2 to 15 years (mean; 10.4 years). The median follow-up period was 64.7 months (from 1 month to 188 months). Pathologic diagnosis were; immature teratoma (n=10), mixed germ cell tumor (n=10), and dysgerminoma (n=6). Tumor stage was classified by the staging system of the International Federation of Gynecology and Obstetrics (FIGO). The number of patients in stage I, II, III, and IV were 24 (75 %), 2 (6.2 %), 4 (12.5 %), and 2 (6.1 %), respectively. The tumor recurred in 4 patients. Seven patients of group 1 did not receive postoperative adjuvant chemotherapy, and in three of them, the tumor recurred. Twenty-five patients (group 2) underwent postoperative adjuvant chemotherapy, and there was only one recurrence. One patient who did not receive postoperative adjuvant chemotherapy and expired 10 months after operation because of tumor recurrence and distant metastasis. The overall 5-year event free survival (EFS) was 84.2 %: group 1 in 44.4 %, and group 2 in 95.7 %. Tumor recurrence was related to the postoperative adjuvant chemotherapy (p=0.004). In conclusion, proper surgical procedures with relevant postoperative adjuvant chemotherapy might improve clinical results in children with malignant ovarian tumors.

Keywords